All In Biotech

Drug Trial Radar · NCT03439254

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Last checked: Nov 20, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 919 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

919

Actual

Start

Aug 30, 2017

Primary completion

Sep 8, 2022

Study completion Sep 8, 2022

Sponsor

Lead sponsor
Intercept PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

Conditions

  • Compensated Cirrhosis
  • Nonalcoholic Steatohepatitis

Interventions

  • Obeticholic acid (10 mg)Drug

    Tablets administered orally once daily.

  • Obeticholic acid (10 mg to 25 mg)Drug

    Tablets administered orally once daily.

  • PlaceboDrug

    Tablets administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)Time frame: Up to 18 months
  2. OLE Phase: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 12 months
  3. OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)Time frame: Baseline and up to Month 12
  4. OLE Phase: Fibrosis-4 (FIB-4) at BaselineTime frame: Baseline (Day 1)
  5. OLE Phase: Enhanced Liver Fibrosis (ELF) at BaselineTime frame: Baseline (Day 1)
  6. OLE Phase: Number of Participants Reporting All-cause MortalityTime frame: Up to Month 12
  7. OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Ascites, Hepatocellular Carcinoma (HCC) and Non-liver Related DeathTime frame: Up to 12 months
  8. OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh ScoreTime frame: Up to 12 months
  9. OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score ≥15Time frame: Up to 12 months

Locations

192 sites in 12 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists of the Southeast

    Dothan, Alabama

  • Objective GI d/b/a North Alabama GI Research Center

    Madison, Alabama

  • Arizona Liver Health

    Chandler, Arizona

  • Arizona Liver Health

    Glendale, Arizona

  • The Institute for Liver Health

    Tucson, Arizona

  • Liver Wellness Center

    Little Rock, Arkansas

  • Arkansas Gastroenterology

    North Little Rock, Arkansas

  • Hope Clinical Research

    Canoga Park, California

  • University of California, San Francisco-Fresno

    Fresno, California

  • Scripps Whittier Diabetes Institute

    La Jolla, California

  • eStudySite

    La Mesa, California

  • Keck Hospital of USC

    Los Angeles, California

  • Cedars-Sinani Medical Center

    Los Angeles, California

  • Palmtree Clinical Research, INC.

    Palm Springs, California

  • Stanford University Medical Center

    Palo Alto, California

  • California Liver Research Institute

    Pasadena, California

  • Inland Empire Liver Foundation

    Rialto, California

  • University of California, Davis Medical Center

    Sacramento, California

  • Kaiser Permanente Sacramento Medical Center

    Sacramento, California

  • University of California, San Francisco

    San Francisco, California

  • University of Colorado Denver and Hospital

    Aurora, Colorado

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado

  • South Denver Gastroenterology, PC

    Englewood, Colorado

  • Innovative Medical Research of South Florida, Inc.

    Aventura, Florida

  • Hi Tech and Global Research LLC

    Coral Gables, Florida

  • Nature Coast Clinical Research

    Inverness, Florida

  • UF Health Jacksonville-Gastroenterology Emerson

    Jacksonville, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Schiff Center for Liver Diseases/University of Miami

    Miami, Florida

  • Sensible Healthcare, LLC

    Ocoee, Florida

  • Innovation Medical Research Center

    Palmetto Bay, Florida

  • Gastroenterology Associates of Pensacola, PA

    Pensacola, Florida

  • Tampa General Medical Group

    Tampa, Florida

  • Guardian Angel Research Center, INC

    Tampa, Florida

  • Florida Medical Clinic, P.A

    Zephyrhills, Florida

  • Summit Clinical Research, LLC

    Athens, Georgia

  • The Emory Clinic (TEC)

    Atlanta, Georgia

  • Gastrointestinal Specialists of Georgia

    Marietta, Georgia

  • Grand Teton Research Group, PLLC

    Idaho Falls, Idaho

  • Rush University Medical Center

    Chicago, Illinois

Showing 40 of 192 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.